Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt(Brigham and Women's Hospital), Michael Szarek(State University of New York), Bertram Pitt(University of Michigan), Christopher P. Cannon(Brigham and Women's Hospital), Lawrence A. Leiter(University of Toronto), Darren K. McGuire(Parkland Health & Hospital System), Julia B. Lewis(University of Colorado Anschutz Medical Campus), Matthew C. Riddle(Oregon Health & Science University), Silvio E. Inzucchi(Yale University), Mikhail Kosiborod(Saint Luke's Hospital), David Z.I. Cherney(University Health Network), Jamie P. Dwyer(University of Colorado Anschutz Medical Campus), Benjamin M. Scirica(Brigham and Women's Hospital), Clifford J. Bailey(Aston University), Rafael Díaz(Estudios Clínicos Latinoamérica), Kausik K. Ray(Imperial College London), Jacob A. Udell(University Health Network), Renato D. Lópes(Duke University), Pablo Lapuerta(Lexicon Pharmaceuticals (United States)), Philippe Gabríel Steg(Inserm)
New England Journal of Medicine
November 16, 2020
Cited by 1,164Open Access
Full Text

Abstract

BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS: of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. RESULTS: Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo. CONCLUSIONS: In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).


Related Papers